The effect of the immunophilin ligands rapamycin and FK506 on proliferation of mast cells and other hematopoietic cell lines.
The immunosuppressive drugs FK506 and cyclosporin A have an identical spectrum of activities with respect to IgE receptor (Fc epsilon RI)-mediated exocytosis from mast cells and T cell receptor-mediated transcription of IL-2. These findings suggest a common step in receptor-mediated signal transduction leading to exocytosis and transcription and imply that immunosuppressive drugs target specific signal transduction pathways, rather than specific cell types. This hypothesis is supported by studies on the effect of rapamycin on IL-3 dependent proliferation of the rodent mast cell line PT18. Rapamycin inhibits proliferation of PT18 cells, achieving a plateau of 80% inhibition at 1 nM. This inhibition is prevented in a competitive manner by FK506, a structural analogue of rapamycin. Proliferation of rat basophilic leukemia cells and WEHI-3 cells was also inhibited, at doses comparable to those shown previously to inhibit IL-2-dependent proliferation of cytotoxic T lymphocyte line (CTLL) cells. In contrast, proliferation of A-431 cells, a epidermoid cell line, was not affected by rapamycin. DNA histograms indicate that complexes formed between the rapamycin-FK506-binding protein (FKBP) and rapamycin arrest-proliferating PT18 cells in the G0/G1-phase. It is concluded that FKBP-rapamycin complexes may inhibit proliferative signals emanating from IL-3 receptors, resulting in growth arrest of cytokine-dependent, hematopoietic cells.
Hultsch
T
T
Allergic Diseases Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.
Martin
R
R
Hohman
R J
RJ
D000818:Animals; D002352:Carrier Proteins; D002460:Cell Line / Q000187:drug effects; D003511:Cyclohexanols; D016193:G1 Phase / Q000187:drug effects; D006410:Hematopoiesis / Q000187:drug effects*; D051379:Mice; D011090:Polyenes / Q000494:pharmacology*; D011714:Pyrans; D051381:Rats; D016185:Receptors, Interleukin-3 / Q000187:drug effects*; D016192:Resting Phase, Cell Cycle / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D020123:Sirolimus; D016559:Tacrolimus / Q000031:analogs & derivatives / Q000494:pharmacology*; D022021:Tacrolimus Binding Proteins
D002352:Carrier Proteins; D003511:Cyclohexanols; D011090:Polyenes; D011714:Pyrans; D016185:Receptors, Interleukin-3; C066205:immunophilin ligand 506BD; D022021:Tacrolimus Binding Proteins; D020123:Sirolimus; D016559:Tacrolimus